Virus inactivation at moderately low pH varies with virus and buffer properties
- PMID: 34874097
- DOI: 10.1002/biot.202100320
Virus inactivation at moderately low pH varies with virus and buffer properties
Abstract
Background: Virus inactivation is a critical operation in therapeutic protein manufacturing. Low pH buffers are a widely used strategy to ensure robust enveloped virus clearance. However, the choice of model virus can give varying results in viral clearance studies. Pseudorabies virus (SuHV) or herpes simplex virus-1 (HSV-1) are frequently chosen as model viruses to demonstrate the inactivation for the herpes family.
Results: In this study, SuHV, HSV-1, and equine arteritis virus (EAV) were used to compare the inactivation susceptibility at pH 4.0 and 4°C. SuHV and HSV-1 are from the same family, and EAV was chosen as a small, enveloped virus. Glycine, acetate, and citrate buffers at pH 4.0 and varying buffer strengths were studied. The inactivation susceptibility was found to be in the order of SuHV > HSV > EAV. The buffer effectiveness was found to be in the order of citrate > acetate > glycine. The smaller virus, EAV, remained stable and infectious in all the buffer types and compositions studied.
Conclusion: The variation in inactivation susceptibility of herpes viruses indicated that SuHV and HSV cannot be interchangeably used as a virus model for inactivation studies. Smaller viruses might remain adventitiously infective at moderately low pH.
Keywords: arteritis virus; bioprocessing; enveloped virus; herpesvirus; viral clearance.
© 2021 Wiley-VCH GmbH.
Similar articles
-
Physiochemical properties of enveloped viruses and arginine dictate inactivation.Biotechnol J. 2021 Jul;16(7):e2000342. doi: 10.1002/biot.202000342. Epub 2021 May 13. Biotechnol J. 2021. PMID: 33877739
-
Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.Biologicals. 2017 Jul;48:24-27. doi: 10.1016/j.biologicals.2017.06.003. Epub 2017 Jun 17. Biologicals. 2017. PMID: 28633975
-
Effects of electrolytes on virus inactivation by acidic solutions.Int J Mol Med. 2011 Jun;27(6):803-9. doi: 10.3892/ijmm.2011.668. Epub 2011 Apr 4. Int J Mol Med. 2011. PMID: 21468540
-
Arginine-enveloped virus inactivation and potential mechanisms.Biotechnol Prog. 2020 Mar;36(2):e2931. doi: 10.1002/btpr.2931. Epub 2019 Nov 11. Biotechnol Prog. 2020. PMID: 31622532 Review.
-
Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.Biologicals. 2007 Oct;35(4):329-34. doi: 10.1016/j.biologicals.2006.11.003. Epub 2007 Mar 23. Biologicals. 2007. PMID: 17363271
Cited by
-
Systematic Development of a Detergent Toolbox as an Alternative to Triton X-100.Biotechnol Bioeng. 2025 May;122(5):1096-1104. doi: 10.1002/bit.28947. Epub 2025 Feb 6. Biotechnol Bioeng. 2025. PMID: 39912529 Free PMC article.
-
Exploring the effects of excipients on complex coacervation.J Colloid Interface Sci. 2025 Oct;695:137808. doi: 10.1016/j.jcis.2025.137808. Epub 2025 May 5. J Colloid Interface Sci. 2025. PMID: 40359635
-
Environmental Stability and Transmissibility of Enveloped Viruses at Varied Animate and Inanimate Interfaces.Environ Health (Wash). 2023 May 30;1(1):15-31. doi: 10.1021/envhealth.3c00005. eCollection 2023 Jul 21. Environ Health (Wash). 2023. PMID: 37552709 Free PMC article. Review.
-
Red Sea Bream Iridovirus Stability in Freeze-Thaw Cycles: Quantitative Assays of Infectious Particles.Animals (Basel). 2025 Jun 9;15(12):1699. doi: 10.3390/ani15121699. Animals (Basel). 2025. PMID: 40564252 Free PMC article.
-
Virucidal N95 Respirator Face Masks via Ultrathin Surface-Grafted Quaternary Ammonium Polymer Coatings.ACS Appl Mater Interfaces. 2022 Jun 8;14(22):25135-25146. doi: 10.1021/acsami.2c04165. Epub 2022 May 25. ACS Appl Mater Interfaces. 2022. PMID: 35613701 Free PMC article.
References
REFERENCES
-
- Barone, P. W., Wiebe, M. E., Leung, J. C., Hussein, I. T. M., Keumurian, F. J., Bouressa, J., Brussel, A., Chen, D., Chong, M., Dehghani, H., Gerentes, L., Gilbert, J., Gold, D., Kiss, R., Kreil, T. R., Labatut, R., Li, Y., Mullberg, J., Mallet, L., … Springs, S. L. (2020). Viral contamination in biologic manufacture and implications for emerging therapies. Nature Biotechnology, 38(5), 563-572.
-
- Johnson, S. A., Brown, M. R., Lute, S. C., & Brorson, K. A. (2017). Adapting viral safety assurance strategies to continuous processing of biological products. Biotechnology Bioeng, 114(1), 21-32.
-
- Liu, H. F., Ma, J., Winter, C., & Bayer, R. (2010). Recovery and purification process development for monoclonal antibody production. mAbs, 2(5), 480-99.
-
- Chinniah, S., Hinckley, P., & Connell-Crowley, L. (2016). Characterization of operating parameters for XMuLV inactivation by low pH treatment. Biotechnology Progress, 32(1), 89-97.
-
- Ma, J., & Roush, D. (2016). Session 1.1: Viral Clearance Using Traditional, Well-Understood Unit Operations: Low pH and Detergent Viral Inactivation. Pda Journal of Pharmaceutical Science and Technology, 70(5), 410-416.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources